Progress and controversies: Radiation therapy for invasive breast cancer by Jagsi, Reshma
Take free quizzes online at acsjournals.com/ce
ONLINE CONTINUING EDUCATION ACTIVITY
After reading the article “Progress and Controversies: Radiation Therapy for Invasive Breast Cancer,” the learner should be able to: 
1. Summarize the role of radiation therapy in breast-conserving therapy and after mastectomy.
2. Name and briefly describe new technologies for breast cancer radiation therapy.
3. Summarize current criteria for considering the use of accelerated partial breast irradiation.
ARTICLE TITLE: Progress and Controversies: Radiation Therapy for Invasive Breast Cancer
CONTINUING MEDICAL EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME)
for physicians.
Blackwell Futura Media Services designates this journal-based CME for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION ACCREDITATION AND DESIGNATION STATEMENT:
The American Cancer Society (ACS) is accredited as a provider of continuing nursing education (CNE) by the American Nurses Credentialing Center’s Commission on
Accreditation.
Accredited status does not imply endorsement by the ACS or the American Nurses Credentialing Center of any commercial products displayed or discussed in
conjunction with an educational activity. The ACS gratefully acknowledges the sponsorship provided by Wiley for hosting these CNE activities.
EDUCATIONAL OBJECTIVES: 
ACTIVITY DISCLOSURES 
No commercial support has been accepted related to the development or publication of this activity.
ACS CONTINUING PROFESSIONAL EDUCATION COMMITTEE DISCLOSURES
Editor, Director of Continuing Professional Education, and ACS Director of Medical Content
Ted Gansler, MD, MBA, MPH, has no financial relationships or interests to disclose.
Deputy Editor and ACS Director of Prostate and Colorectal Cancers
Durado Brooks, MD, MPH, has no financial relationships or interests to disclose.
Lead Nurse Planner and Associate Editor 
Marcia Grant, RN, PhD, FAAN, has no financial relationships or interests to disclose.
American Academy of Family Physicians representative and Associate Editor
Richard C. Wender, MD, has no financial relationships or interests to disclose.
AUTHOR DISCLOSURES 
Reshma Jagsi, MD, DPhil is on the Medical Advisory Board of Eviti, Inc. She is the recipient of active grants from the National Institutes of Health, the ACS,
the National Comprehensive Cancer Network, the Burroughs-Wellcome/Alliance for Academic Internal Medicine, and the Breast Cancer Research Foundation.
She has also received support for drug and distribution only from Abbott Pharmaceuticals for an investigator-initiated study.
CNECME
SCORING
A score of 70% or better is needed to pass a quiz containing 10 questions (7 correct answers), or 80% or better for 5 questions (4 correct answers).
INSTRUCTIONS ON RECEIVING CME CREDIT
This activity is intended for physicians. For information concerning the applicability and acceptance of CME credit for this activity, please consult your professional
licensing board.
This activity is designed to be completed within 1 hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully
earn credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.
CME
INSTRUCTIONS ON RECEIVING CNE CREDIT
This activity is intended for nurses. For information concerning the applicability and acceptance of CNE credit for this activity, please consult your professional licensing
board.
This activity is designed to be completed within 1.0 hours; nurses should claim only those credits that reflect the time actually spent in the activity. To successfully earn
credit, participants must complete the activity during the valid credit period, which is up to 2 years from the time of initial publication.
FOLLOW THESE STEPS TO EARN CREDIT
•  Log on to and acsjournals.com/ce.
•  Read the target audience, educational objectives, and activity disclosures. 
•  Read the activity contents in print or online format. 
•  Reflect on the activity contents. 
•  Access the examination, and choose the best answer to each question. 
•  Complete the required evaluation component of the activity. 
•  Claim your certificate.
This activity will be available for CME/CNE credit for 1 year following its launch date. At that time, it will be reviewed and potentially updated and extended for an
additional 12 months.
All CME/CNE quizzes are offered online FREE OF CHARGE. Please log in at acsjournals.com/ce. New users can register for a FREE account. Registration will allow you to
track your past and ongoing activities. After successfully completing each quiz, you may instantly print a certificate, and your online record of completed courses will be
updated automatically.
CNE
135SPONSORED BY THE AMERICAN CANCER SOCIETY, INC. VOLUME 64  |  NUMBER 2  |  MARCH/APRIL 2014
Progress and Controversies: Radiation Therapy
for Invasive Breast Cancer
Reshma Jagsi, MD, DPhil1
Radiation therapy is a critical component of the multidisciplinary management of invasive breast cancer. In appropriately
selected patients, radiation not only improves local control, sparing patients the morbidity and distress of local recurrence, but it
also improves survival by preventing seeding and reseeding of distant metastases from persistent reservoirs of locoregional dis-
ease. In recent years, considerable progress has been made toward improving our ability to select patients most likely to benefit
from radiotherapy and to administer treatment in ways that maximize clinical benefit while minimizing toxicity and burden. This
article reviews the role of radiation therapy in invasive breast cancer management, both after breast-conserving surgery and after
mastectomy. It focuses particularly on emerging evidence that helps to define the clinical situations in which radiotherapy is indi-
cated, the appropriate targets of treatment, and optimal approaches for minimizing both the toxicity and the burden of treatment,
all in the context of the evolving surgical and systemic management of this common disease. It includes a discussion of new
approaches in breast cancer radiotherapy, including hypofractionation and intensity modulation, as well as a discussion of prom-
ising avenues for future research. CA Cancer J Clin 2014;64:135-152. V
C
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Introduction
Radiation therapy is a critical component of the multidisciplinary management of invasive breast cancer. In appropriately
selected patients, radiation therapy not only improves local control, sparing patients the morbidity and distress of
local recurrence, but it also improves survival, presumably by preventing seeding and reseeding of distant metastases from
persistent reservoirs of locoregional disease. In recent years, considerable progress has been made toward improving our
ability to select patients most likely to benefit from radiotherapy and to administer treatment in ways that maximize clinical
benefit while minimizing toxicity and burden.
This article reviews the role of radiation therapy in invasive breast cancer management, both after breast-conserving
surgery and after mastectomy. It focuses particularly on emerging evidence that helps to define the clinical situations in which
radiotherapy is indicated, the appropriate targets of treatment, and optimal approaches for minimizing both the toxicity and
the burden of treatment, all in the context of the evolving surgical and systemic management of this common disease.
Radiation as Part of Breast-Conserving Therapy
Randomized trials comparing breast conservation with mastectomy have firmly established equivalent survival in appropri-
ately selected patients, allowing most women with early stage disease to choose this more limited surgical procedure without
compromising disease control. Radiation therapy has long been recognized as a key component of breast-conserving therapy
and has been recommended in consensus guidelines for over 2 decades.1,2
1Associate Professor, Department of Radiation Oncology, Research Investigator, Center for Bioethics and Social Science in Medicine, University of
Michigan, Ann Arbor, MI
Corresponding author: Reshma Jagsi, MD, DPhil, Department of Radiation Oncology, University of Michigan, UHB2C490, SPC 5010, 1500 East Medical Center
Drive, Ann Arbor, MI 48109-5010; rjagsi@med.umich.edu
DISCLOSURES: Dr. Jagsi is on the Medical Advisory Board of Eviti, Inc.; she is the recipient of active grants from National Institutes of Health, the American
Cancer Society, the National Comprehensive Cancer Network, the Burroughs-Wellcome=Alliance for Academic Internal Medicine, and the Breast Cancer Research
Foundation; and she has received support for drug and distribution only from Abbott Pharmaceuticals for an investigator-initiated study.
doi: 10.3322/caac.21209. Available online at cacancerjournal.com
136 CA: A Cancer Journal for Clinicians
Radiation Therapy for Breast Cancer
Initially, recommendations for radiation were grounded
in results from individual randomized trials comparing
breast-conserving surgery with and without adjuvant radio-
therapy that suggested a substantial benefit from radio-
therapy in reducing locoregional recurrence. For example,
in the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-06 randomized trial, the 20-year ipsilateral
breast tumor recurrence rate was 14.3% after lumpectomy
with whole breast radiation versus 39.2% after lumpectomy
alone.3 Only more recently has the impact of radiotherapy
on overall survival in this setting been demonstrated.
The Early Breast Cancer Trialists’ Collaborative Group
meta-analysis first demonstrated in 2005 that the reduction
in recurrence afforded by radiotherapy in this setting also
provides a modest benefit in overall survival.4 In the most
recent update of the meta-analysis, which included 10,801
women in 17 trials of radiation or no radiation after
lumpectomy, radiation reduced the 10-year risk of any
recurrence in lymph node-negative women from 31% to
15.6% and reduced the 15-year risk of death from breast
cancer from 20.5% to 17.2%.5
However, not all subgroups of patients attain the same
absolute benefit from radiotherapy, and the survival benefit
from treatment appears to be restricted to those patients
who reap a large absolute reduction in recurrence risk from
treatment rather than those in whom the absolute benefit
in recurrence risk reduction is under 10% or even between
10% and 20%.
Seeking a Population With Favorable Features
in Whom Omission of Radiation Is Safe After
Breast-Conserving Surgery
Given the burden, morbidity, and cost of adjuvant radio-
therapy, researchers have sought to identify a low-risk
population of patients for whom the risk of recurrence in
the absence of radiotherapy might be sufficiently small
that omission of radiotherapy might reasonably be consid-
ered. Over 2 decades ago, in an early observational study,
Nemoto et al remarked that, of 122 women who underwent
lumpectomy alone, at a median of 4 years, none with a
tumor size < 1 cm had recurred.6
Unfortunately, studies seeking to identify a subgroup of
patients who could undergo breast-conserving surgery with-
out radiotherapy, based upon clinicopathologic characteris-
tics alone, have largely proved unsuccessful. For example,
investigators at Harvard conducted a prospective study of
lumpectomy alone in selected women with unicentric T1N0
invasive cancers of favorable histology (without extensive
intraductal component or lymphovascular invasion) treated
with a wide excision of pathologically negative margins
measuring 1 cm.7 No systemic therapy was given, and
receptor testing was not required. The mean tumor size in
that study was 0.9 cm, and the median age was 67 years.
At 7 years of follow-up, the local recurrence rate was unac-
ceptably high at 23%. Similarly, in a Finnish trial of
patients with T1N0 disease who did not receive adjuvant
endocrine therapy, the 12-year local recurrence rate was
27% among patients who did not receive radiotherapy after
segmental resection.8
Because systemic therapy has an impact on locoregional
control, the NSABP conducted the B-21 randomized trial
in the hope of identifying whether tamoxifen might be
used in lieu of adjuvant radiation in selected patients.9 That
study randomized 1009 women who had invasive breast
cancers 1 cm in size after lumpectomy and negative
margins (defined as no tumor on ink) to 1 of 3 treatments:
tamoxifen alone, radiation alone, or tamoxifen and radia-
tion. Estrogen receptor testing was not required, and 20%
of patients were aged <50 years. Patients who received
tamoxifen alone had an 8-year risk of ipsilateral breast
tumor recurrence of 16.5% compared with 9.3% for patients
who received radiation alone and 2.8% for patients who
received both tamoxifen and radiation, leading the authors
to conclude that adjuvant radiotherapy was necessary even
in patients who had small tumors in the era of tamoxifen.
Similarly, a Canadian multicenter trial randomized
patients aged 50 years who had T1-T2, N0 tumors to
receive either radiation plus tamoxifen or tamoxifen
alone.10 Again, the overall findings were disappointing,
with unacceptably high rates of local recurrence (7.7% at 5
years and 18% at 8 years after tamoxifen alone). Even in the
subgroup with T1N0, estrogen receptor-positive tumors,
the 8-year rate of local recurrence was 15.2%. A German
trial with a 23 2 factorial design demonstrated a large
excess of local recurrences when both radiation and
endocrine therapy were omitted but suggested that event-
free survival might be similar in patients treated with
endocrine therapy, radiation, or both.11 However, the
limited sample size and corresponding low statistical power
to detect differences constrained the impact of this finding.
An Austrian trial that randomized 869 women to undergo
breast-conserving surgery and hormonal therapy with or
without radiotherapy revealed a 5-year local relapse rate of
0.4% with radiotherapy versus 5.1% without radiotherapy,
with no differences in distant metastases or overall survival;
however, the group reported that, by 6 years, that difference
had increased to 0.4% versus 9%.12 Thus, they concluded
that longer follow-up was necessary before reaching solid
conclusions, and future research should seek to investigate
whether an even more favorable subgroup can be prospec-
tively defined.
To date, only 1 study has been interpreted by many
as having successfully identified a limited subgroup of
patients in whom the long-term risk of local recurrence
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after breast-conserving surgery and endocrine therapy alone
is low enough to consider the omission of radiotherapy:
Cancer and Leukemia Group B (CALGB) 9343.13 In
that trial, 636 women aged 70 years with clinical stage
T1N0M0, estrogen receptor-positive, invasive cancers
received lumpectomy with negative margins (with or with-
out axillary assessment) and tamoxifen for 5 years and were
randomized to receive whole breast radiation versus obser-
vation. Radiation therapy decreased the risk of locoregional
recurrence; and, at 10 years, 98% of patients who received
radiotherapy were free from locoregional recurrence com-
pared with 90% of those who did not receive radiotherapy.
However, given the lack of difference in time to mastec-
tomy, time to distant metastasis, breast cancer-specific
survival, and overall survival,14 many have concluded that
the omission of radiation may be a reasonable option for
elderly women with clinicopathologically favorable cancers
who intend to receive endocrine therapy. Still, questions
remain regarding whether the outcomes in CALGB
9343 are generalizable to patients who have risk factors
like high-grade tumors, lymphovascular invasion, or close
margins; to those who have a longer life expectancy; or to
those who may be less compliant with endocrine therapy
than the population that participated in the trial.
Hypofractionation
Because tens of thousands of women each year continue
to require adjuvant radiotherapy after breast-conserving
surgery, various alternative approaches to minimize the
burden of treatment have been sought. Traditionally, radia-
tion treatment after breast-conserving surgery has targeted
the whole breast with total doses of 45 to 50 Gray (Gy)
administered in 1.8- to 2-Gy daily fractions, followed in
many centers by an additional 10- to 15-Gy boost dose
to the tumor bed, for a total of 5 to 6 weeks of daily
treatment.15 Unfortunately, the cost and inconvenience of
multiple weeks of radiation treatment may be a barrier to
the use of breast-conserving therapy instead of mastectomy
in some populations and may also partially explain the
failure of some patients to receive the radiation therapy that
is indicated after breast-conserving surgery.16,17
Hypofractionation of radiation treatment involves the
use of larger daily doses of radiation and decreases the total
number of fractions that must be administered. Radio-
biologic studies have suggested that breast cancer cells have
a relatively low “alpha-beta ratio,”18,19 which indicates that
it may well be possible to maintain equivalent tumor
control with shorter hypofractionated schedules delivering
lower total doses. Hypofractionation may involve treatment
to the whole breast, or it may involve treatment to only part
of the breast. The following sections discuss these 2
approaches in turn.
Hypofractionated Whole Breast Irradiation
Studies of hypofractionated whole breast radiation have a
long history. Studies in the 1960s revealed substantial
toxicity when the total dose was maintained and larger frac-
tions were administered. Therefore, more recent attempts
at hypofractionation have investigated the use of a larger
dose per fraction along with a reduced total dose in an
attempt to maintain normal tissue tolerance.20
Several trials have investigated the use of hypofrac-
tionated regimens of irradiation to the whole breast. For
example, a large Canadian trial enrolled 1234 women with
invasive, lymph node-negative breast cancer treated by
lumpectomy with negative pathologic margins.21 Patient
accrual was limited to women of small to moderate breast
size (breast separation  25 cm), and few patients received
adjuvant systemic chemotherapy. The trial randomized
women to receive hypofractionated whole breast irradiation
of 42.5 Gy in 16 fractions over 22 days versus standard
whole breast irradiation of 50 Gy in 25 fractions over 35
days. Acute toxicity was low and was similar between the
arms, with grade 2 or 3 radiation skin toxicity observed in
3% of patients in each arm. Two cases of radiation pneu-
monitis developed in each arm, and 1 rib fracture developed
in the standard arm.
More important, long-term outcomes also were similar
between the arms. The 10-year risk of local recurrence was
6.2% in the hypofractionated arm and 6.7% in the standard
arm, and the rate of good or excellent cosmesis was 69.8%
in the hypofractionated arm and 71.3% in the standard
arm.22 Thus, hypofractionated whole breast irradiation has
been shown to yield similar disease control and cosmetic
outcomes, with considerably greater convenience, in
patients with characteristics similar to those of patients
entered on that study. However, the uptake of hypofrac-
tionation has not been uniform, even in Ontario. Although
the importance of financial incentives to deliver greater
numbers of radiation fractions may play some role in limit-
ing the enthusiasm of US practitioners regarding this
approach, the observation of a more limited impact of
trial results than expected, even in Ontario, suggests that
certain other barriers may have limited the diffusion of
this approach into practice.23,24 These barriers may include
concerns about extrapolating the findings from that study
to patients with larger body habitus or those receiving
chemotherapy, as well as concerns about how to incorpo-
rate a radiation boost, which was discovered to be of
benefit after the Canadian trial was already completed.25
Moreover, some have noted that the overall rate of good to
excellent cosmesis is somewhat lower than that observed in
many US institutional series,26 and long-term results
regarding potential late effects in adjacent organs (such as
the heart, which may take considerably longer to demon-
strate late toxicity) have yet to mature.
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Other data supporting hypofractionation come from the
United Kingdom. In a randomized trial, 1410 patients were
randomized to receive either standard fractionated whole
breast irradiation or 1 of 2 nonaccelerated but hypofractio-
nated schedules of 42.9 Gy or 39 Gy in 13 fractions over 5
weeks.27 After 10 years, the proportion of patients who
were free from moderate to marked breast induration was
63.7% in patients who received 50 Gy, 48.9% in those who
received 42.9 Gy, and 72.3% in those who received 39 Gy.
A subset of 723 patients were randomly assigned to receive
either boost irradiation of 14 Gy delivered by electrons to
the tumor bed or no boost; and an additional 687 patients
received boost as part of their standard treatment. Patients
who were randomized to boost irradiation had significantly
higher rates of induration and telangiectasia.
The UK Standardization of Radiotherapy A (START
A) trial built upon these findings by comparing 50 Gy in
25 fractions over 5 weeks with 41.6 Gy or 39 Gy in 13 frac-
tions over 5 weeks in 2236 patients. Photographic assess-
ments were similar between the 50-Gy and 41.6-Gy arms,
but there were lower rates of change in breast appearance
after 39 Gy than after 50 Gy, with a hazard ratio of 0.69
(P5 .01). The START B trial compared 50 Gy in 25 frac-
tions over 5 weeks versus 40 Gy in 15 fractions over 3 weeks
in 2215 women. In that study, at a median follow-up of 6
years, photographic and patient assessments suggested lower
rates of late adverse effects in the accelerated hypofractionated
arm (P5 .06 for photographic change in breast appearance).
Further studies are underway to build upon these find-
ings. In the British FAST trial, women received even
higher doses per fraction—50 Gy in 25 fractions, 30 Gy in
5 fractions, or 28.5 Gy in 5 fractions, all over 5 weeks—and
maturation of the results will provide further interesting
information on these issues.28 In the United States, there is
ongoing investigation of the incorporation of a concurrent
boost with the use of intensity-modulated radiotherapy
(IMRT).29 These approaches hold significant promise for
reducing the burden of adjuvant radiation treatment in
patients undergoing breast-conserving surgery.
Accelerated Partial Breast Irradiation
Inspired by evidence that the majority of failures after
breast-conserving therapy occur in the vicinity of the tumor
bed30-32 and the belief that it is possible to identify patients
who have a low risk of residual disease remote from the lum-
pectomy cavity,33 investigators have also begun to explore
the possibility that an even more radically accelerated sched-
ule of hypofractionated radiation might be tolerable if one
treats only part of the breast. By further shortening treat-
ment time, those developing these techniques of accelerated
partial breast irradiation (APBI) hope that they may increase
access to breast-conserving therapy for more women.34
Moreover, it is possible that, by decreasing the volume of
irradiated tissue, these techniques might lead to a decrease in
treatment-related toxicity. In addition, because chemother-
apy is still recommended in many patients with early stage
disease, the potential for using APBI so that neither radia-
tion nor chemotherapy is delayed by the other is appealing.35
However, because other studies have shown that recurrences
may develop outside even a generous volume beyond the pri-
mary tumor36 and that microscopic disease may extend far
from the original primary site,37-39 both the toxicity and the
effectiveness of APBI are the subjects of considerable
ongoing investigation.
Various techniques are now available to deliver APBI.
The earliest studies employed multicatheter brachytherapy
techniques. A particularly early series from Guy’s Hospital,
London,40,41 before the implementation of more rigorous
patient selection and advances in dosimetric planning,
reported a relatively high rate of ipsilateral breast recurrence
of 37% among patients who received low-dose-rate brachy-
therapy alone after lumpectomy. However, more recent
studies with proper patient selection and techniques have
reported much lower rates of local recurrence after brachy-
therapy. For example, in the series of 199 strictly selected
patients who received multicatheter brachytherapy at the
William Beaumont Hospital,32,42,43 the 5-year actuarial
local recurrence rate was 1%, and the 12-year rate was 5%.
This rate of local recurrence was not statistically different
from the rate of local recurrence observed in a matched
group of patients who received standard whole breast
radiation. Infections were documented in 11% of patients,
and fat necrosis—78% of which occurred in patients
who had asymptomatic findings on mammography—was
documented in 21%. Infection rates were higher with open
(8.5%) versus closed (2.5%) cavity placement of the intersti-
tial needles (P5 .005). Promising results were also reported
in other early, single-institution series in the United
States44-48 and in a multi-institutional Radiation Therapy
Oncology Group (RTOG) phase 1=2 study that was initi-
ated in 1995,49 in which the actuarial 4-year rate of breast
recurrence was 3% and the 4-year lymph node recurrence
rate was also 3%. Long-term follow-up of certain specific
series50 has also illuminated that careful attention to tech-
nique, treatment planning, dose prescription, and total dose
is important to avoid excess toxicity.51 Modern interstitial
brachytherapy tends to employ high-dose-rate treatment,
like that used for the majority of patients who received
partial breast irradiation on a small Hungarian randomized
trial conducted from 1998 to 2004, in which no differences
in local control were observed between those who received
partial versus whole breast irradiation, and those treated
with partial breast irradiation had significantly better
cosmetic outcomes.52
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Ultimately, the quality of a multicatheter implant depends
on the skill of the radiation oncologist who places the cathe-
ters. Because experience with interstitial brachytherapy of
the breast has decreased in recent years as electron-beam
therapy has become the most common means by which to
administer breast boost treatments, alternative, potentially
more user-friendly devices for brachytherapy have been
developed in recent years. Promising results with single-
lumen balloon brachytherapy were reported approximately 1
decade ago by investigators associated with the manufacturer
of the MammoSite device53,54 and others.55
However, some have raised concerns regarding the
outcomes of single-lumen brachytherapy, at least as it was
performed in the early days of its development. In a highly
publicized observational study of Medicare claims data,
patients undergoing brachytherapy-based APBI had a higher
mastectomy rate than those who received whole breast irra-
diation (3.95% vs 2.18%; P< .001).56 However, it is impor-
tant to note that this study considered the relatively early
experience with brachytherapy, before criteria for appropriate
patient selection and risk factors for complications had
been articulated,57 so its results may not reflect the toxicity
or efficacy of brachytherapy as it is currently applied, now
that experience with this approach is more mature.58 For
example, delayed catheter insertion may help to reduce what
otherwise may be a substantial risk of persistent seroma
formation.59 Several institutions have reported favorable
experiences with the approach, and a multi-institutional
registry study by the American Society of Breast Surgeons
recently reported a 90.6% rate of excellent or good cosmetic
outcomes at 84 months, with rates of symptomatic seroma,
fat necrosis, infection, and telangiectasia of 13.4%, 2.5%,
9.6%, and 13.0%, respectively.60 However, given the poten-
tial for selection bias in these latter studies, debate continues
in this area. More recently, interest has grown in the use of
single-entry, multichannel applicators for the administration
of high-dose-rate brachytherapy, given apparent dosimetric
advantages from these approaches.61-64
Interest has also grown regarding the possibility of deli-
vering partial breast irradiation with intraoperative treat-
ment. Access is also increasing to technologies that allow
for the delivery of a single fraction of radiation therapy
while the patient is still on the operating table, before the
surgical wound is closed. Initially, European investigators
initiated studies of this approach. Using intraoperative elec-
tron therapy,65,66 Veronesi and colleagues reported on a
series of 237 patients who were treated with single-fraction
doses of 17 to 21 Gy using electron energies of 3 to 9 mega-
electron volts (MeV) administered with a portable linear
accelerator.67 After a median follow-up of 71 months,
among 119 patients who were selected randomly from 1200
cases treated, grade 2 fibrosis was observed in 32%, and
grade 3 fibrosis was observed in 6%.68 Preliminary results
from the intraoperative radiation therapy with electrons
(ELIOT) randomized trial revealed a significant difference
in local recurrence with this approach (5.3% after a single
intraoperative fraction of 21 Gy vs 0.7% with standard,
fractionated whole breast radiotherapy).69 Researchers at
the University of North Carolina have investigated intra-
operative electron radiotherapy delivered before segmental
mastectomy, delivering at least 15 Gy to the tumor plus a
margin.70,71 That group observed an alarmingly high 6-year
rate of ipsilateral events (15%), and most of those events
occurred in patients who had less favorable clinicopatho-
logic features. In contrast, investigators at University
College London have administered radiation using the
Intrabeam, a miniature electron-beam–driven source of
low-energy x-rays (50 kilovolts).72,73 In the large targeted
intraoperative radiotherapy (TARGIT-A) trial,74 women
with invasive ductal carcinoma were randomized to this
approach versus whole breast external-beam radiotherapy.
The 4-year rates of local recurrence were 1.20% in the
intraoperative therapy group and 0.95% in the external-
beam treatment group for the low-risk population that
accrued to the study. Still, the shallow coverage offered
with this technique has raised concerns regarding rates of
in-breast tumor recurrence with longer follow-up.
Therefore, many investigators have turned their attention
toward the possibility of accomplishing partial breast irradia-
tion using fractionated conformal external-beam approaches,
which are now possible given the improvements in target
localization and dosimetric planning. External-beam treat-
ment is noninvasive, allows treatment after full pathologic
information is available without subjecting the patient to
a second surgical procedure, and may be less operator-
dependent compared with brachytherapy. Increased homo-
geneity of dose with external-beam therapy may reduce the
complications from fat necrosis observed in brachytherapy
series, but determining the appropriate dose for tumor
control by extrapolating from doses used in the brachy-
therapy studies has been difficult precisely because of these
large differences in dose homogeneity between techniques.
The most commonly used fractionation scheme for
high-dose-rate brachytherapy has been 3.4 Gy delivered
twice daily over 5 days, a schedule that was developed to be
radiobiologically equivalent to a standard 5-week course of
radiation and to minimize the time exposed to indwelling
brachytherapy catheters, which increases the risk of infec-
tion. Those developing external-beam partial breast irradia-
tion explored alternative schedules in order to address the
differences in dose homogeneity with this approach.
In an early randomized trial, Christie Hospital’s Holt
Radium Institute treated 708 patients using either wide-
field radiation therapy with 4-megavolt photons to a dose
of 40 Gy in 15 fractions over 21 days or limited field radia-
tion with 8- to 14-MeV electrons to a dose of 40 to
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42.5 Gy in 8 fractions over 10 days.75 After a median
follow-up of 65 months,76 a larger percentage of patients
who received radiation to limited fields versus wide fields
had marked telangiectasias (33% vs 12%) or marked fibro-
sis (14% vs 5%). Subsequent single-institutional studies
generally used more cautious dosing schedules and more
advanced planning techniques.
Investigators at New York University developed a
technique of 3-dimensional (3D) conformal external-beam
APBI in the prone position,77,78 administering 30 Gy to
the tumor bed plus a 1.5- to 2-cm margin in 5 fractions
within 10 days, which produced promising results.79 Inves-
tigators at the William Beaumont Hospital developed a
technique of 3D conformal external-beam APBI performed
in the supine position.80 In contrast to the parallel-opposed
minitangents generally used by the New York University
group, the Beaumont group used 4 to 5 noncoplanar
photon beams. The dose prescribed was 34 Gy to the
tumor bed plus expansion in the first 6 patients and 38.5
Gy in the remainder, all in 10 fractions, again with promi-
sing outcomes.81,82 The latter fractionation scheme was
embraced by other institutions and was used for patients
receiving conformal external radiation for partial breast
irradiation on the large RTOG 0413=NSABP B-39
randomized trial seeking to explore both the efficacy and
toxicity of partial breast irradiation further.83
As use of this approach spread, evidence emerged to
suggest that the significantly higher integral dose to the
normal breast84 with this approach might cause detriment to
cosmetic outcomes. Single-arm trials at Tufts85,86 and the
University of Michigan87 suggested that rates of adverse
cosmetic outcomes might be more substantial than usually
observed with standard whole breast irradiation. However,
an interim analysis of toxicity among patients enrolled on
the large RTOG 0413=NSABP B-39 randomized trial
revealed extremely low rates of severe toxicity in those receiv-
ing external-beam partial breast irradiation, as reported on
physician case report forms using the Common Toxicity
Criteria for Adverse Events.88
Recently, compelling evidence of a substantial negative
impact of external-beam partial breast irradiation on cos-
metic outcomes has been provided from the large, multi-
center RAPID (Randomized Trial of Accelerated Partial
Breast Irradiation) trial in Canada, which randomized
patients to external-beam APBI, using a schedule of 38.5
Gy in 10 fractions, versus whole breast irradiation. Adverse
cosmetic outcomes were more common in the patients who
received APBI as assessed by trained nurse observers (29%
vs 17%; P< .001), the patients themselves (26% vs 18%;
P5 .002), and blinded physician reviewers of photographs
(35% vs 17%; P< .001). Therefore, additional research is
necessary to identify which patients are most likely to expe-
rience adverse cosmetic outcomes after external-beam par-
tial breast irradiation and to further refine dosimetric
parameters and perhaps the dosing schedules themselves89
for this approach.
In summary, in appropriately selected patients, and with
appropriate techniques, APBI indeed may prove to be a
safe and effective approach. Still, continued study is neces-
sary, because only after mature data from randomized trials
have been analyzed can the safety and efficacy of this treat-
ment strategy be determined. Numerous ongoing and
recently completed trials in the United States and abroad
have been designed to evaluate both the efficacy and the
safety of partial breast irradiation and will yield illuminat-
ing results along these lines in the coming years. Consensus
guidelines do exist to guide patient selection while trial
data mature.57,90,91 Table 1 provides a summary of consen-
sus guidelines developed by the American Society of Radia-
tion Oncology. Nevertheless, given the rapidly evolving
evidence regarding partial breast irradiation, patients
should be fully informed of the nascent nature of our
understanding in this area and encouraged to participate in
clinical protocols whenever possible.
IMRT
Interest in reducing the burden of radiotherapy has also led
in recent years to the investigation of techniques that may
reduce treatment-related toxicity. Two-dimensional (2D)
wedged techniques of radiotherapy delivery are limited by
the fact that the breast contour varies considerably from the
superior-most to the inferior-most aspect of the breast.
Consequently, although a simple wedge may achieve excel-
lent homogeneity along the central axis of the breast, sub-
stantial areas of dose higher than that prescribed (so-called
“hot spots”) may exist at other levels (see Fig. 1). These hot
spots, in turn, may lead to both acute and late toxicity.
With the development of 3D treatment planning systems
and the now widespread availability of linear accelerators
with multileaf collimation capabilities, it has become possi-
ble to provide differential segmental blocking of the radia-
tion beam through the treatment field to reduce hot spots
in the dose distribution (see Fig. 2). This has led to an
interest in administering radiation to the breast in several
segmented fields, using either forward planning or inverse
planning to determine beam weighting. This technique has
commonly been called “breast IMRT.” It is noteworthy
that this relatively simple technique, which aims primarily
to improve dose homogeneity, differs from the inverse-
planned beamlet intensity modulation that is usually
employed in other treatment sites with the aim of improv-
ing dose conformality.92
Investigators from William Beaumont Hospital observed
decreased rates of dermatitis and edema in patients who
were treated with a forward-planned IMRT technique
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using multiple segments than among patients who were
treated with 2D planning in an earlier era .93-98 Researchers
at Fox Chase Cancer Center also compared patients who
were treated using IMRT with patients who were treated
in an earlier era with 2D plans and observed a decrease in
acute desquamation.99
A Canadian randomized trial in 358 patients compared
breast IMRT versus 2D wedged treatment and reported a
reduction in acute moist desquamation from 47.8% to 31.2%
with the use of an IMRT technique that consisted of a mean
of 4 to 6 segments.100 Moreover, in another randomized
trial, the British Breast Technology Group reported
improvements in long-term cosmesis in patients randomized
to IMRT compared with those randomized to standard 2D
wedge-compensated treatment.101 Still, although it is clear
that intensity modulation leads to decreased toxicity
TABLE 1. “Suitable,” “Cautionary,” and “Unsuitable” Patient Groups for Accelerated Partial Breast Irradiation*
FACTORS “SUITABLE” GROUP “CAUTIONARY” GROUP “UNSUITABLE” GROUP
Patient factors
Age, y 60 50 to 59 <50
BRCA1/2 mutation Not present NA Present
Pathologic factors
Tumor size, cm 2† 2.1–3.0† >3†
T stage T1 T0 or T2 T3 or T4
Margins Negative by at least 2 mm Close (<2 mm) Positive
Grade Any NA NA
LVSI No‡ Limited/focal Extensive
ER status Positive Negative§ NA
Multicentricity Unicentric only NA If present
Multifocality Clinically unifocal with total size 2 cmk Clinically unifocal with total size 2.1 to
3.0 cmk
If microscopically multifocal >3 cm in total
size or if clinically multifocal
Histology Invasive ductal or other favorable subtypes** Invasive lobular NA
Pure DCIS Not allowed 3 cm in size If >3 cm in size
EIC Not allowed 3 cm in size If >3 cm in size
Associated LCIS Allowed NA NA
Nodal factors
N stage pN0 (i2, i1) NA pN1, pN2, pN3
Nodal surgery SN Bx or ALND†† NA None performed
Treatment factors
Neoadjuvant therapy Not allowed NA If used
*Patients are suitable for APBI if all criteria in “suitable” column are satisfied. Any of the criteria in the “cautionary” column should invoke caution and concern
when considering APBI. Any of the criteria in the “unsuitable” column render patients unsuitable for APBI outside of a clinical trial. Criteria are derived from
data (when available) and conservative panel judgment.
†The size of the invasive tumor component as defined by the American Joint Committee on Cancer.
‡The finding of possible or equivocal LVSI should be disregarded.
§Patients with ER-negative tumors are strongly encouraged to enroll in the National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy and
Oncology Group 04–13 clinical trial.
kMicroscopic multifocality allowed, provided the lesion is clinically unifocal (a single discrete lesion by physical examination and ultrasonography/mammog-
raphy) and the total lesion size (including foci of multifocality and intervening normal breast parenchyma) does not exceed 2 cm for the “suitable” group and
3 cm for the “cautionary” group.
**Favorable subtypes include mucinous, tubular, and colloid.
††Pathologic nodal staging is not required for ductal carcinoma in situ.
ALND, axillary lymph node dissection; APBI, accelerated partial breast irradiation; EIC, extensive intraductal component; ER, estrogen receptor; LCIS, lobular
carcinoma in situ; LVSI, lymph-vascular space invasion; NA, the given criteria are not applicable; SN Bx, sentinel lymph node biopsy.
Reprinted with permission from Smith BD, Arthur DW, Buchholz TA, et al Accelerated partial breast irradiation consensus statement from the American Society
for Radiation Oncology (ASTRO). J Am Coll Surg. 2009;209:269–277, Copyright (2009), with permission from Elsevier.57
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compared with 2D planning, the question of how many seg-
ments are actually necessary to achieve the observed benefit
and whether this treatment merits being billed at the sub-
stantially higher IMRT charge code remains the subject of
ongoing discussion and investigation.102
Postmastectomy Radiotherapy
Appropriate selection of patients for postmastectomy radia-
tion therapy continues to be another major subject of
research and controversy. In patients at sufficient risk for
harboring residual disease in the chest wall and regional
lymph nodes after mastectomy and systemic therapy, radia-
tion therapy not only may prevent morbid local recurrence
but also may improve survival, presumably by eliminating
an isolated microscopic reservoir of residual disease from
which distant metastases may be seeded or reseeded after
initial elimination by effective systemic therapy. However,
not all patients have the same risk of harboring residual
locoregional disease after mastectomy and systemic therapy
or of that reservoir being an isolated one. Therefore, a key
subject of research has been to identify which patients are
likely to benefit from treatment.
Early randomized trials of postmastectomy radiation
generally demonstrated a reduction in the risk of locore-
gional recurrence of breast cancer without improvement in
overall survival, particularly before the advent of effective
systemic therapies.103-106 As experience with systemic ther-
apy for breast cancer grew, it became increasingly apparent
that certain subgroups of patients might harbor a burden of
residual locoregional disease that systemic therapies could
not eradicate and, thus, might benefit from the admini-
stration of postmastectomy radiation therapy. Therefore,
several trials were initiated to explore the role of postmas-
tectomy radiation in conjunction with chemotherapy.107-112
Unfortunately, those early studies were designed before the
late toxicity of radiation therapy was fully appreciated and
sophisticated techniques of radiation field design were not
yet available. Meta-analysis of those older studies revealed
that the benefits in terms of disease control ultimately were
offset by significant treatment-related toxicities, likely
related to the exposure of large volumes of the heart and
lungs to high doses of radiation.113-116
Subsequent trials ultimately did reveal a substantial ben-
efit from postmastectomy radiation therapy in terms of
both locoregional control and overall survival, and these tri-
als have served as the foundation of existing clinical practice
guidelines. These studies included mostly lymph node-
positive patients along with a smaller number of individuals
with locally advanced, lymph node-negative disease.
In a Danish trial of premenopausal patients, postmastec-
tomy radiation therapy yielded both a substantial reduction
in locoregional failure (from 32% to 9%) and a significant
improvement in overall survival (the 10-year overall survival
FIGURE 1. Dose Distribution With Simple Wedged Tangential Breast Radiotherapy. This figure demonstrates the inhomogeneity in dose that can occur
when open, tangential, opposed photon beams with a single lateral wedge are applied to a typical breast. Like a topographic map, the peaks and val-
leys in dose are depicted here, including “hot spots” in which portions of tissue receive a higher dose than other regions. In this case, there are rela-
tively large hot spots (as depicted in red). Figure courtesy of Robin Marsh, CMD.
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rate improved from 45% to 54%; P< .001). On multivariate
analysis, the study indicated that primary tumor size, the
number of involved lymph nodes, grade, age, and use of
radiotherapy were all significant independent predictors of
outcome; no interactions were observed between radiother-
apy and the other characteristics, so the results suggested
that the benefit of radiotherapy existed for all subgroups.
Moreover, no difference in survival was observed between
patients with left-sided and right-sided disease in the initial
report at 10 years, and a separate publication that consid-
ered ischemic heart disease morbidity and mortality
revealed no excess risk of ischemic heart disease in irradi-
ated patients versus unirradiated patients.117
Similar findings were reported in a Danish trial con-
ducted in postmenopausal patients,118 in whom postmas-
tectomy radiation therapy also led to both a reduction in
locoregional recurrence (from 35% to 8%) and improve-
ment in overall survival (the 10-year overall survival rate
improved from 36% to 45%; P5 .03). In a smaller but sim-
ilarly designed Canadian trial in premenopausal patients,
the 20-year survival rate improved from 37% to 47%
(P5 .03) with postmastectomy radiation therapy.119
Meta-analyses that included the results from these more
recent trials have suggested that radiation therapy after mas-
tectomy does indeed improve both local control and overall
mortality.120,121 Perhaps the most influential of these has
been the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis,4 which reported in a landmark
2005 publication that, among 8340 women who underwent
mastectomy and axillary clearance for lymph node-positive
disease and enrolled in trials of radiation therapy (generally
to the chest wall and regional lymph nodes) through 1995,
the 5-year local recurrence risk was reduced from 22.8% to
5.8%, with a 15-year breast cancer mortality risk of 54.7%
versus 60.1% (reduction, 5.4%; 2-sided P5 .0002) and an
overall mortality reduction of 4.4% (64.2% vs 59.8%; 2-sided
P5 .0009). This led the EBCTCG to conclude that there
was a 4:1 ratio, such that, for every 4 local recurrences pre-
vented at 5 years, 1 life was saved.
Nevertheless, concerns have been raised about the exter-
nal validity or generalizability of the Danish and Canadian
trials. These include concerns about the systemic therapies
administered in the era during which the trials were con-
ducted and concerns regarding the adequacy of surgery per-
formed in these trials.122 In the Danish 82b and 82c trials,
the median number of lymph nodes removed was only 7,
and 255 patients on the 82b trial had fewer than 4 lymph
nodes removed. Because so few lymph nodes were exam-
ined, there may have been substantial underestimation of
the true number of involved lymph nodes, such that
patients characterized as having only 1 to 3 involved lymph
nodes in the Danish trials might well have been categorized
as having  4 involved lymph nodes if a more complete
level I and II axillary lymph node dissection had been per-
formed. Furthermore, residual disease in the axilla might
have necessitated radiation therapy in a way that may not
FIGURE 2. Segmented Breast Intensity-Modulated Radiotherapy. This fig-
ure demonstrates differential segmental blocking of the radiation beam
through the treatment field to reduce hot spots in the dose distribution.
(Top) Specifically, the first row shows an open medial tangent beam fol-
lowed by 2 segmentally blocked beams, and the second row shows the
open, lateral tangent beam followed by 2 segmentally blocked beams.
These segmentally blocked beams deliver a small proportion of the total
dose and improve the homogeneity of the total dose distribution. (Middle)
This graph demonstrates that most of the treated volume receives the
prescribed dose, and a very small amount receives slightly less or more
(homogeneity, 65%). Gy indicates Gray. (Bottom) This schematic demon-
strates the angles from which these treatments are administered. Figure
courtesy of Robin Marsh, CMD.
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be the case when a more extensive axillary lymph node dis-
section is performed. Indeed, this idea is supported by the
finding that the axilla was a component of locoregional
recurrence in 13% of unirradiated patients in the Danish tri-
als,123 contrasting sharply with the much lower rates gener-
ally expected from complete level I and II dissection.124,125
Indeed, retrospective analyses of patients who had 1 to 3
positive lymph nodes after mastectomy and did not receive
radiation treatment have demonstrated considerably lower
absolute rates of locoregional recurrence than the rates
observed in the unirradiated patients on the Danish and
British Columbian trials, ranging from 10-16%.126-129
Given these findings, which diverge substantially from the
rates of locoregional failure observed in unirradiated
patients who had 1 to 3 involved lymph nodes in the Dan-
ish and British Columbia studies, it has been unclear
whether radiation therapy is indicated for this subgroup of
patients in the United States. Consensus guidelines have
tended to clearly recommend postmastectomy radiation for
patients who have  4 involved lymph nodes but are more
equivocal regarding decisions for patients who have 1 to 3
involved lymph nodes.130-133 For example, the guidelines of
the National Comprehensive Cancer Network are provided
in Table 2.134
Of note, in 2007, the Danish investigators published a
pooled reanalysis of a subset of the patients treated on the
82b and 82c trials who had  8 lymph nodes removed.135
Even within this subgroup, there was a survival benefit, and
that benefit had the same absolute magnitude (9%) among
patients who had 1 to 3 involved lymph nodes as among
patients who had  4 involved lymph nodes, although the
locoregional recurrence rates were lower in the former
group. This led the authors to debate the EBCTCG’s argu-
ment for a 4:1 ratio between locoregional recurrence pre-
vention and survival, noting that the survival benefit of
postmastectomy radiation therapy is likely related to the
ability of systemic therapy to eliminate any existing meta-
static deposits at the time of diagnosis. Therefore, they
concluded that radiation therapy may be particularly impor-
tant in the subgroup of patients who have less extensive
lymph node involvement, in whom the burden of distant
disease at diagnosis is likely to be less substantial (and
potentially more amenable to elimination by systemic
therapies) or absent. In light of these data, taken together
with the evidence described above, the most recent set of
consensus guidelines from the National Comprehensive
Cancer Institute state that patients with 1 to 3 involved
lymph nodes who undergo mastectomy should “strongly
consider” radiation therapy.
Patients without lymph node involvement may also be
considered for radiation therapy in select circumstances.
One such group is those who present with large or other-
wise locally advanced primary tumors.136,137 The Danish
trials suggested benefit in that population, with an
improvement in both locoregional recurrence (from 17% to
3%) and survival (from 70% to 82%) in premenopausal
patients and an improvement in locoregional recurrence in
the postmenopausal group (from 23% to 6%). However,
more recent retrospective studies have suggested that the
risk of locoregional recurrence without radiotherapy in
patients with lymph node-negative tumors measuring  5
cm in size may be 10% or less—more modest than origi-
nally expected.138,139 However, few tumors of extremely
large size were included in those retrospective studies, so
patients with T3N0 tumors still warrant consultation with
a radiation oncologist, who may discuss these data with the
patient to facilitate individualized decision-making.
The decision regarding whether to pursue radiation ther-
apy in patients with borderline T3N0 disease may be fur-
ther illuminated by some insights gained from retrospective
studies of lymph node-negative patients that included
patients with smaller primary tumors.140-142 These studies
TABLE 2. NCCN Guidelines for Patient Selection for Postmastectomy Radiation Therapy Among Patients With
Operable Invasive Breast Cancer
FEATURES RECOMMENDATION
4 Positive axillary lymph nodes Radiation therapy to the chest wall, supraclavicular, and infraclavicular regions;
strongly consider radiation to the internal mammary region
1–3 Positive axillary lymph nodes Strongly consider radiation therapy to the chest wall, supraclavicular, and
infraclavicular regions; if giving radiation, strongly consider radiation to the
internal mammary region
Negative axillary lymph nodes and tumor
>5 cm or positive margins
Consider radiation therapy to the chest wall with or without supraclavicular and infraclavicular lymph nodes;
strongly consider radiation therapy to internal mammary lymph nodes
Negative axillary lymph nodes, and tumor
5 cm, and close margins (<1 mm)
Consider radiation therapy to chest wall
Negative axillary lymph nodes, and tumor
5 cm and margins 1 mm
No radiation therapy
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have identified several risk factors for locoregional recur-
rence in lymph node-negative patients undergoing mastec-
tomy. These risk factors include young patient age, larger
tumor size, close or involved surgical margins, the presence
of lymphovascular invasion, the omission of systemic ther-
apy, and high nuclear grade. It may be useful to consider
these factors when deciding whether a patient is likely to
benefit from postmastectomy radiation therapy.
Particular attention has been given to the implications of
close or positive surgical margins. Several retrospective
studies have addressed this issue.143 In a cohort from Brit-
ish Columbia, trends for a higher risk of locoregional recur-
rence were observed in early stage patients with positive
surgical margins after mastectomy if they were aged <50
years versus 50 years (20% vs 0%), had T2 tumors versus
T1 tumors (19.2% vs 6.9%), had high-grade disease versus
low-grade or intermediate-grade disease (23.1% vs 6.7%),
or had lymphovascular invasion present versus absent
(16.7% vs 9.1%).144 More recently, in a large series from
Boston, patients who had positive margins had a 5-year
locoregional recurrence rate of 6.2%, but patients who had
close ( 2 mm) margins had a risk of only 1.5% (similar to
the 1.9% risk observed in patients with negative mar-
gins).145 Thus, margin status is an important consideration
when determining whether to offer postmastectomy radio-
therapy, but the level of evidence to guide practice in this
area is less well established than in others.
Finally, a particularly active area of research concerns
patients who have received systemic therapy in the neoadju-
vant setting. Because the research regarding postmastectomy
radiation therapy described above was conducted in patients
who received the more traditional sequence of surgery fol-
lowed by systemic therapy, much of our understanding of the
role of radiation therapy after mastectomy relies on pathologic
staging that was conducted before exposure to systemic thera-
pies. Extrapolating from those data to the situation of patients
who have received systemic therapy before definitive patho-
logic evaluation has been complicated.146
Retrospective studies from the MD Anderson Cancer
Center have provided insights regarding the role of radiation
therapy in patients undergoing mastectomy after neoadju-
vant chemotherapy.147 These studies have suggested that the
extent of disease both at diagnosis and after neoadjuvant
chemotherapy are relevant considerations. Even patients
who experience a pathologic complete response to neoadju-
vant chemotherapy appeared to have a substantial reduction
in locoregional recurrence risk with radiation therapy if they
had initially presented with clinical stage III disease (33%
risk vs 3% risk). However, no locoregional recurrences were
observed for those who achieved a pathologic complete
response after diagnosis with earlier stage disease.148
Similarly, in a retrospective analysis of locoregional
recurrence patterns in patients treated on the NSABP B18
and B27 randomized trials of preoperative systemic ther-
apy,149 in whom postmastectomy radiation was not allowed
per protocol, only 1 recurrence was observed in 94 patients
who had a pathologic complete response, regardless of
tumor size and clinical lymph node status. These studies
have inspired a national randomized trial to explore the role
of postmastectomy radiation, as well as regional lymph
node radiation, in patients who experience the eradication
of lymph node disease by preoperative systemic therapy.
In sum, the oncology community continues to debate the
potential value of postmastectomy radiation therapy for cat-
egories of “intermediate-risk” breast cancer, in which data
have proven insufficient to warrant definitive recommenda-
tions by expert panels. However, there is strong consensus
regarding the role of postmastectomy radiation in patients
with truly locally advanced disease. Indeed, a survey of radi-
ation oncologists indicated that the vast majority (>98%)
reported that they would offer radiation to at least the chest
wall in patients with 4 involved lymph nodes, although
there was less consensus regarding patients with T3N0 dis-
ease (in which 88.3% would offer postmastectomy radiation
therapy to the chest wall), and even less for patients who
had 1 to 3 involved lymph nodes (with 85.2% offering post-
mastectomy radiation therapy to at least the chest wall if
lymph node extracapsular extension was noted and 61.7%
offering it if extracapsular extension were absent).15 Thus,
all patients with locally advanced breast cancer merit refer-
ral to radiation oncology, and postmastectomy radiation
therapy is considered to be an integral component of their
multimodal management.
Management of the Regional Lymph Nodes
The rationale for radiation therapy to the regional lymph
nodes is the same as that articulated for postmastectomy
radiation therapy. In select patients with lymph node
involvement, the regional lymph node basins may be the
only reservoir of residual disease after local surgery and sys-
temic therapy. Eradication of that reservoir, if isolated,
could improve survival. The Danish and Canadian post-
mastectomy trials included treatment to the supraclavicular,
axillary, and internal mammary lymph nodes; and some
have extrapolated from those trials that radiation therapy to
those regions also should be considered for patients who
undergo breast-conserving surgery.
In patients who have undergone complete level I=II axil-
lary node dissections, there is generally consensus that
directed radiotherapy to the axilla is unnecessary. However,
axillary dissection is no longer routine in patients with posi-
tive lymph nodes. The American College of Surgeons
Oncology Group Z0011 trial randomized patients who had
clinical T1=T2 invasive breast cancer, no palpable adenopa-
thy, and 1 to 2 sentinel lymph nodes containing metastases
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to axillary lymph node dissection versus no further axillary
surgery. In the patients who were treated on this trial, among
whom a substantial proportion had micrometastatic disease
and the vast majority of whom received adjuvant endocrine
therapy, survival was equivalent between the 2 arms at 6.3
years. Although the study protocol recommended standard
tangential radiotherapy, the radiation treatment was not
audited, and it is possible that the radiation oncologists who
treated patients on that trial did indeed use high tangent
fields or other techniques for directed axillary treatment.
Therefore, many practitioners in the United States have con-
sidered treatment to the axilla if undissected after a positive
sentinel lymph node biopsy.150
Much debate surrounds the appropriate management of
the supraclavicular and internal mammary lymph node
regions in patients who have positive axillary lymph nodes
but no clinical evidence of involvement in those regions. In
the National Cancer Institute of Canada MA20 trial, 1832
patients who underwent breast-conserving surgery were
randomly assigned to receive radiation therapy to the breast
either alone or in conjunction with treatment to the
regional lymph nodes. Preliminary results suggested a 5.4%
absolute improvement in distant disease-free survival and a
2.3% benefit in locoregional disease-free survival from the
addition of radiation therapy to the supraclavicular and
internal mammary regions. Of course, the MA20 trial did
not isolate the impact of supraclavicular versus internal
mammary radiation, nor did the European Organization
for Research and Treatment of Cancer 10925 trial, which
still remains to be analyzed. Supraclavicular fields are gen-
erally less controversial, given that a nontrivial minority of
failures occur in this region,151 and it is believed that treat-
ment results in little if any increase in the risks of pneumo-
nitis, brachial plexopathy, and lymphedema. In contrast,
concerns about the potential cardiac and pulmonary toxicity
associated with treating the parasternal internal mammary
lymph node region are significant. This has led to particular
controversy surrounding treatment to the internal mam-
mary region in particular152-154 and widespread variation in
practice patterns.155 Considerable controversy remains
regarding the need to treat this region,156 and practice
varies widely. The current National Comprehensive Cancer
Network guidelines recommend strong consideration of
treatment to the internal mammary lymph nodes.
Toxicity Concerns
In addition to the concerns about cosmetic outcomes of
breast conservation discussed above, particular attention
has been devoted in recent years to the potential cardiac
toxicity of breast radiotherapy. As noted above, the cardio-
toxic effects of older techniques, which exposed large vol-
umes of the heart to high doses of radiation, have been
clearly established.157 More recent studies have raised con-
cerns about even more conformal, modern techniques. The
left anterior descending coronary artery may be incidentally
irradiated to high doses by tangential fields, and treatment
to the internal mammary lymph node region also can result
in dose to the right coronary vessels.
Reassuringly, population-based studies have suggested
that the magnitude of increased cardiac risk related to radi-
ation therapy may have decreased in more recent years.158
However, it is sobering that perfusion defects (for which
the clinical consequences have yet to be defined) have been
observed even in patients treated with relatively modern
techniques.159 Several single-institution studies have sug-
gested that there may be an increase in the relative risk of
ischemic cardiac events after radiation therapy for left-sided
breast cancer, although the absolute magnitude of this
increased risk appears to be low.160 Recent studies have also
suggested that radiation and other cardiac risk factors, such
as hypertension or smoking, may be synergistic in their
effects.161,162 A recent population-based case-control study
has highlighted the importance of minimizing the radiation
dose to the heart.163 However, it is important to note that
the net survival benefit of radiation therapy that was docu-
mented in the trials discussed above and in the meta-
analysis already accounted for any adverse impact of cardiac
toxicity on survival. Therefore, although reducing the radi-
ation dose to cardiac structures is a worthy and important
endeavor, patients with a substantial likelihood of net bene-
fit should not avoid treatment solely because of concerns
related to cardiac exposure. Careful treatment planning,
including consideration of sophisticated technology and
respiratory gating in cases where cardiac anatomy is unfav-
orable, is essential to ensure that cardiac dose and the
attendant risks are minimized.
Conclusions and Directions for Future
Research
Considerable progress has occurred in our knowledge
regarding appropriate patient selection and techniques for
radiation in the treatment of breast cancer. Efforts continue
to reduce the burden of radiotherapy in the setting of breast
conservation, including the possibility of defining a subgroup
that may safely avoid radiation altogether in an era of increas-
ingly effective systemic therapy, as well as to ensure the appro-
priate targeting of treatment in the setting of mastectomy.
Further research is necessary to define those patients at high-
est risk for radiation-related toxicity as well as to define the
optimal management of that toxicity when it occurs.
In recent years, the field of oncology has begun to appre-
ciate that breast cancer is a heterogeneous disease in which
tumor biology can be at least as important as clinicopatho-
logic stage in determining outcomes. Therefore, interest
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has been growing in the evaluation of outcomes by biologic
subtype as well as in defining genomic predictors of
recurrence.164,165 Already, retrospective studies have begun
to evaluate the influence of subtype upon locoregional
recurrence risk and response to radiotherapy.166-169
Further research along these lines may be particularly valu-
able in the quest to better individualize locoregional ther-
apy for breast cancer, ensuring that treatment is targeted
toward those most likely to benefit and sparing those at
lower risk from unnecessary toxicity and burden. 
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